Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cautionary findings on acquired immunodeficiency from anti-CD20 MS therapy

Key clinical point: Development of low IgM and IgG in response to anti-CD20 therapy for MS is of particular concern during the COVID-19 pandemic.

Major finding: Mean time to development of low IgM on anti-CD20 therapy was 19.7 months.

Study details: This was a retrospective study of more than 500 MS patients followed for a mean of 30 months on anti-CD20 therapies.

Disclosures: The presenter reported having no financial conflicts regarding her study.


Vollmer BL et al. AAN 2020. Abstract S29.002.